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Abstract
Pancreatic cancer remains a leading cause of cancer-related deaths. Most patients are 
present with advanced stages of the disease at the time of diagnosis; thus, surgery, which 
is the best curative option for this malignancy, is no longer an effective treatment modal-
ity for affected individuals. As a likely source of “liquid biopsies,” exosomes, which are 
secreted by fusing intracellular multivesicular bodies with cell membranes, have relative 
stability and composition, allowing them to cover the entire range of cancer-related bio-
markers, including cellular proteins, lipids, DNA, RNA, miRNA, and long non-coding 
RNAs (lncRNAs). To explore the early detection biomarkers of pancreatic cancer and to 
develop successful therapeutic intervention for this disease, assessing the implications of 
exosomes in pancreatic cancer patients is essential. In this chapter, we wish to focus on 
the possibility of using exosomes and lncRNAs in the clinical management of patients 
with pancreatic cancer. We will discuss the mechanisms of tumor formation under the 
exosomal action, demonstrate how circulating exosomes and lncRNAs have come into 
the research spotlight as likely biomarkers of pancreatic cancer, and discuss the applica-
tions of exosomes as transfer vectors in tumor therapeutics.
Keywords: exosomes, lncRNA, pancreatic cancer, biomarkers, diagnosis, therapeutic 
intervention
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1. Introduction
1.1. Exosomes, ncRNAs, and lncRNAs
Exosomes are a class of small (40–120 nm) extracellular vesicles (EVs) that originate in mul-
tivesicular endosomes [1–3] and can be released from a wide range of cells, including can-
cer cells [4]. Exosomes differ in size from microvesicles (50–1000 nm) and apoptotic bodies 
(800–5000 nm) and are secreted directly from the cell membrane in a budding form [5–7]. Late 
endosomes released from multivesicular bodies (MVBs) are integrated with the cell mem-
brane in the extracellular matrix during the release of exosomes. Exosomes released into the 
extracellular environment can be utilized by tumor cells to alter the tumor microenvironment 
or to provide a favorable microenvironment for distant metastases by affecting distant organs 
[8–10]. Therefore, exosomes serve as efficient vehicles for long- and short-distance intercel-
lular communication by signaling molecules in the form of lipids, proteins, DNA, RNAs, and 
non-coding RNAs (ncRNAs) [11]. Exosomes play an important role in signal transduction 
between cells.
In the complicated human genome, approximately 2% of the genomic sequence encodes 
proteins involved in biological progression [12], of which approximately 90% are ncRNAs. 
ncRNAs are described as the “noise” of the genome in their primary form, and they can be 
divided into two subgroups: small ncRNAs (sncRNAs) and long ncRNAs (lncRNAs) [13–16]. 
If RNA is <200 nt in length, the ncRNAs are defined as sncRNAs, which includes microRNAs 
(also called miRNAs or miRs). Conversely, long non-coding RNAs (lncRNAs) are >200 nt in 
length. Previous studies have reported that lncRNAs are involved in numerous physiological 
and pathological processes.
In recent years, an increasing number of lncRNAs have been investigated, and play a vital role 
in various major biological processes associated with promoting proliferation, invasion, and 
migration metabolism [17–19]. Increasing evidence points to important functional or regula-
tory roles of lncRNAs in cellular processes, including the cell cycle, proliferation, apoptosis 
[20–22], RNA processing [23], chromatin modification [24, 25], genomic reprogramming [26, 
27], and gene imprinting [28]. They also play a role in cancers resulting from aberrant lncRNA 
expression. Recent findings indicate that lncRNAs are dysregulated in many kinds of cancer, 
including pancreatic cancer (PaCa), and they are closely related with tumorigenesis, metasta-
sis, prognosis, and diagnosis.
2. The physiological function of exosomes
Exosomes carry a variety of substances from secreted cells, including proteins, lipids, 
DNA, RNA, and ncRNA [29, 30]. The intercellular communication regulated by exosomes 
is not only involved in regulating the physiological processes of normal cells but also par-
ticipates in many pathological processes associated with disease development, including 
tumors [31–33]. Exosomes regulate biological activity through the rapid reaction of signal 
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molecules on their surface or by the release of extracellular biologically active substances. 
Exosomal biological activity is mainly determined by its components (i.e., the exosome 
cell source) [8–10]. Exosomes, which use autocrine, paracrine, and endocrine signaling to 
exchange biological information, are involved in the transmission of substances and signals 
between cells.
In addition, exosomes have immunomodulatory function [34]. Antigen-presenting cell 
(APC)-derived exosomes can promote the proliferation of T lymphocytes and induce anti-
tumor immune responses in vivo. Exosomes have the features of their original cells because 
they bring DNA, RNA, and proteins from the original cell and carry a variety of proteins on 
their surface. Since exosomes are released from endosomes, they carry certain endosomal-
specific proteins, including GTPases, flotillin, Alix, Tsg101, CD81 and CD82, heat shock pro-
teins Hsp70 and Hsp90, and epithelial cell adhesion molecules [35–38] that are involved in 
exosome formation.
If exosomes are secreted by tumor cells, they can kill the tumor cells by providing information 
to cytotoxic T lymphocytes by cross-reacting with antigen-presenting cells [39]. However, 
exosomes from tumor cells have a dual role in that they have antitumor activity and also 
promote tumor growth. For example, exosomes from colorectal cancer cells contain cell cycle-
related mRNAs that promote the proliferation of endothelial cells, which can induce tumor 
angiogenesis [40]. Exosomes obtained from gastric cancer cells promote tumor progression 
by activating the NF-kB pathway in macrophages [41]. In ovarian cancer, epithelial ovarian 
cancer (EOC) cell-derived exosomes promote ovarian cancer metastasis and deterioration by 
transferring CD44 to peritoneal cells [42].
3. Exosomes as novel biomarkers of cancer
The identification of cancer-specific exosomes in bodily fluids, such as serum, plasma, and 
urine, will be useful for the detection of cancer and will allow for the identification of specific 
DNA, RNA, and protein content in the absence of contamination from non-cancerous exosomes 
[43]. The proteoglycan glypican-1 (GPC1) is highly expressed in tumor cell-derived exosomes. 
GPC1 has been shown to be a specific, sensitive marker in serum from pancreatic patients 
that are in both the early and late stages but not in benign pancreatic diseases [43]. CD24 and 
EpCAM are tumor-derived exosome markers isolated by immune-affinity techniques involv-
ing anti-CD24 and anti-EpCAM magnetic beads [44]. In serum, CD24 and EpCAM serve as 
early diagnosis biomarkers [44], while fibronectin can serve as an early diagnosis biomarker 
in plasma. The ELISA method has been used to detect fibronectin [45]. The levels of exosomal 
EDIL3 from breast cancer patients can be dramatically reduced with surgery, indicating that 
EDIL3 can also serve as a diagnostic and prognostic biomarker [46]. Survivin expression 
has been shown to be significantly increased in patients with prostate cancer, but lower sur-
vivin expression has been found in benign prostatic hyperplasia (BPH) and healthy subjects. 
Additionally, the levels of survivin in BPH and healthy subjects are not significantly different. 
Thus, survivin can be used as a new diagnostic indicator of prostate cancer [47].
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Separated and purified exosomes not only contain mRNA and miRNA but also tRNA and 
some lncRNA [11, 48–50]. Six miRNAs (miR-19b-3p, miR-21-5p, miR-221-3p, miR-409-3p, 
miR-425-5p, and miR-584-5p) were found to be upregulated in lung adenocarcinoma [51]. 
Eight miRNAs (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205, and miR-
214) have served as diagnostic biomarkers for ovarian cancer, and these miRNAs have also 
been identified in exosomes from ovarian cancer patients [52]. miRNAs can also be diagnostic 
biomarkers for esophageal squamous cell cancer (ESCC), as the serum levels of exosomal 
miR-21 from patients with ESCC are significantly higher than those of patients with benign 
diseases without systemic inflammation and are positively correlated with tumor progression 
and aggressiveness [53].
4. Exosomes for therapeutic intervention in cancer
The recent contribution by Zhang et al. reviewed the recent advances in cancer immunother-
apy, exosome functions, exosome immunoregulation, and immune cell-derived exosomes 
[34]. As mentioned in Zhang’s manuscript, exosomes cannot only transfer messages between 
cells by carrying RNA and proteins but also can modulate the immune response. After 
reviewing recent findings regarding exosomes and immunity in cancer, we have highlighted 
the novel insights into the development of efficient exosome-based cancer vaccines for cancer 
therapeutic intervention. Specifically, exosomes derived from immune cells, such as APCs, 
dendritic cells (DCs), and NK cells, play a crucial role in the immunomodulation of cancer, 
and they may be the best cancer vaccine candidates because they can inhibit the malignant 
activity of cancer cells and leave healthy cells unaffected [54–56]. Recently, researchers have 
noted that exosomes may lead to key advances in cancer therapy. Exosomes isolated from 
DCs have been evaluated in clinical trials as treatment for various kinds of cancers [57–59]. In 
a phase I clinical trial, exosomes derived from autologous DCs loaded with MAGE 3 peptides 
were applied as cancer therapy for stage III/IV melanoma patients [58]. Several phase I or 
phase II clinical trials involving exosome-based regimens have occurred in breast cancer, gas-
tric cancer, malignant glioma, and non-small cell lung cancer patients, which demonstrates 
that exosomes are effective tools for the transportation of anticancer drugs [59]. Exosomes 
were employed to form a complex with curcumin and delivered to recipient pancreatic cancer 
cells, which was found to promote cytotoxicity [60]. Moreover, exosomes have been shown 
to deliver small, molecular anticancer drugs across the blood-brain barrier and significantly 
inhibit tumor growth in a brain cancer model [61, 62].
5. Long non-coding RNAs as novel biomarkers in cancer
lncRNAs modulate gene expression, while lncRNA dysregulation is associated with human 
cancer. lncRNAs could play a significant role in cancer progression by interacting with pro-
teins. Since they are highly specific and easily detectable in tissue, serum, plasma, and urine, 
interest in exploring lncRNAs in cancer patients continues to increase. Metastasis-associated 
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lung adenocarcinoma transcript 1 (MALAT-1, also known as NEAT2), a novel lncRNA, is 
found on chromosome 11q13 and is well conserved among mammalian species. MALAT-1 
is a critical regulator of the metastatic phenotype of lung cancer cells [63] and can enhance 
proliferation, cell motility, invasion, and metastasis in CNE-1 [64], lung adenocarcinoma [65], 
thyroid cancer [17], cervical cancer [19], and ovarian cancer cells [18]. MALAT-1 has an impor-
tant role in regulating the metastasis of bladder cancer and can be a potential application 
in bladder cancer therapy [66]. The MALAT-1-mediated promotion of renal cell carcinoma 
(RCC) proliferation and metastasis may be due to the upregulation of Livin expression [67]. 
MALAT-1 promotes the proliferation of chondrosarcoma cells via activating the Notch-1 
signaling pathway [68], indicates poor prognosis in non-small cell lung cancer, and induces 
migration and tumor growth [69]. Upregulation of MALAT-1 has been associated with sur-
vival rate, cell cycle, and migration in patients with esophageal squamous cell carcinoma 
(ESCC) [70]. However, the loss of MALAT1 is compatible with cell viability and normal devel-
opment [71]. On the other hand, MALAT-1 is downregulated in preeclampsia and regulates 
the proliferation, apoptosis, migration, and invasion of JEG-3 trophoblast cells [72]. MALAT-1 
is also expected to be a potential therapeutic target in prostate cancer [73]. As another criti-
cal oncogenic lncRNA in human cancers [74, 75], the lncRNA HOTTIP promotes tumor 
growth, inhibits cell apoptosis [76], contributes to the progression of prostate cancer [77] and 
non-small cell lung cancer [78] by regulating HOXA13, and increases the chemoresistance 
of osteosarcoma cells by activating the Wnt/β-catenin pathway [79]. HOTTIP is upregulated 
and associated with poor prognosis in patients with osteosarcoma [80]. Overexpression of 
HOTTIP can promote tumor invasion and predict poor prognosis in gastric cancer [81]. This 
accumulating evidence indicates that long non-coding RNAs have immense potential as pow-
erful, non-invasive tumor markers. However, overexpression of HOTTIP inhibits glioma cell 
growth by brain and reproductive expression [82].
Circulating lncRNAs have shown potential as biomarkers in the diagnosis and prognosis of 
many cancers, including cervical cancer, colon cancer, hepatocellular carcinoma (HCC), gas-
tric cancer (GC), PaCa, renal cell carcinoma (RCC), ovarian cancer (OC), non-small cell lung 
cancer (NSCLC), thyroid cancer, and prostate cancer (Table 1). Here, we have identified some 
interesting circulating lncRNAs (also known as exosomal lncRNAs), including MALAT-1, 
PVT1, HOTAIR, H19, UCA1, and TUG1, as novel biomarkers in various cancers. MALAT-1 
in urine may serve as a potential biomarker for predicting prostate cancer risk. The applica-
tion of the MALAT-1 model can prevent 30.2–46.5% of unnecessary biopsies in high-grade 
cancers [83]. PVT1 expression has been shown to be significantly elevated in non-small cell 
lung cancer (NSCLC), and high PVT1 expression has been associated with poor overall sur-
vival and disease-free survival in NSCLC patients; therefore, PVT1 could serve as a promising 
biomarker for the diagnosis and prognosis of NSCLC. PVT1 knockdown could remarkably 
inhibit NSCLC cell proliferation [84]. HOTAIR has been shown to be significantly higher in 
breast cancer patients, and circulating HOTAIR DNA levels were 2.15-fold higher in patients 
compared with those of healthy controls in one study, which demonstrates a moderate cor-
relation between its expressions in tumor tissues. Plasma HOTAIR levels have been found to 
be significantly reduced after surgery [85, 86], indicating that plasma HOTAIR might serve 
as a potential biomarker for diagnosing breast cancer. A multivariate survival analysis also 
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lncRNA Functions Detection in cancer References
MALAT-1 1. Promotes cell 
proliferation, invasion, and 
migration
Thyroid cancer, OC, 
cervical cancer, NSCLC, 
human nasopharyngeal 
carcinoma cell lines, 
bladder cancer, lung 
adenocarcinoma, JEG-3 
trophoblast cells, PaCa, 
chondrosarcoma cell, RCC, 
ESCC
[17–19, 66, 67, 71–75, 77, 
106]
2. Regulator of the 
metastasis
Lung cancer cells, human 
nasopharyngeal carcinoma 
cell lines, PaCa
[65, 66, 111]
3. Diagnostic and 
prognostic biomarker
Prostate cancer (urine/
plasma), osteosarcoma 
(serum)
[78, 88, 123]
4. Potential therapeutic 
target
Prostate cancer [78]
HOTTIP 1. Inhibits glioma cell 
growth
Glioma [87]
2. Cell growth, apoptosis, 
migration, and invasion
HCC, PaCa, GC and 
colorectal cancer, NSCLC, 
lung cancer
[80, 81, 83, 85, 113, 123]
3. Increases 
chemoresistance
Osteosarcoma cell, PaCa [119]
4. Progression and 
prognosis
Prostate cancer, colorectal 
cancer, osteosarcoma, 
tongue squamous cell 
carcinoma, PaCa, HCC
[80, 82, 119, 124–126]
5. Biomarkers PaCa (blood) [121]
PVT1 1. Promotes cell 
proliferation and invasion
NSCLC, esophageal cancer, 
bladder cancer, acute 
promyelocytic leukemia, 
GC, BC
[127–133]
2. Progression and 
prognosis
Cervical cancer, GC, HCC, 
PaCa
[115, 134–137]
3. Promotes resistance OC, GC [138, 139]
4. Modulates thyroid 
cancer cell proliferation
Thyroid cancer [140]
5. Apoptosis Colorectal cancers [141]
6. Novel biomarker for 
diagnosis and prognosis
Cervical cancer, HCC, RCC 
(Serum); PaCa, NSCLC 
(tissue)
[89, 114, 142–145]
uc.345 1. Promotes tumorigenesis PaCa [122]
LINC-PINT 1. Diagnostic and 
prognostic biomarkers
PaCa (plasma and tumor 
tissues)
[127]
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lncRNA Functions Detection in cancer References
HOTAIR 1. Enhances cell 
proliferation, survival and 
migration
PaCa, HCC, cervical cancer, 
GC, OC, NSCLC, colorectal 
cancer, prostate cancer
[113, 146–155]
2. Enhances its prognostic 
potential and correlates 
with disease progression
BC, HCC, cervical cancer, 
bladder cancer
[156–169]
3. Relative to resistance BC, cervical cancer, OC, 
bladder transitional cell 
carcinoma
[157, 160–162]
4. Associated with EMT, 
cancer stem cells
Epithelial OC, colorectal 
cancer
[163, 164]
5. Activates autophagy HCC [165]
6. Modulates HLA-G 
expression
Cervical cancer, GC [166, 167]
7. Potential biomarker for 
diagnosis
PaCa, BC, colorectal 
carcinoma (serum/plasma), 
PaCa (tissue), GC (tissue, 
blood, and gastric juice)
[90, 91, 114, 149, 168–170]
H19 1. Promotes cell 
proliferation, migration 
and invasion
PDAC, lung cancer, BC, 
glioblastoma
[117, 172–174]
2. Prognosis and 
progression and Metastasis
Gastrointestinal, colorectal 
cancer, NSCLC, gallbladder 
carcinoma
[175–179]
3. Regulates angiogenesis Glioma, glioblastoma [173, 180]
4. Contributing to 
resistance
OC [181]
5. Modulates 
tumorigenicity and 
stemness
Malignant carcinoma [182]
6. Regulatory role 
in pluripotency and 
tumorigenesis
Human embryonic 
carcinoma
[183]
7. Promotes EMT Colorectal cancer, 
esophageal cancer, 
glioblastoma
[173, 184, 185]
8. Potential biomarkers for 
diagnosis
GC (serum/plasma/tissue), 
BC (tissue), bladder cancer
[91–93, 186–188]
IRAIN 1. Promotes proliferation 
and suppresses apoptosis
PaCa, NSCLC [123, 189]
2. As a novel imprinted 
gene that is aberrantly 
regulated in breast cancer
BC (tumors and peripheral 
blood leucocytes)
[190]
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indicated that H19 might serve as a potential biomarker for early detection and prediction of 
prognosis of breast cancer and gastric cancer. The expression of H19 was remarkably increased 
in breast cancer and gastric cancer tissues. H19 expression has been shown to be significantly 
correlated with invasion depth, advanced TNM stage and regional lymph node metastasis in 
gastric cancer. Additionally, elevated expression levels of H19 have been shown to contribute 
to the poor overall survival and disease-free survival of gastric cancer patients [87]. This makes 
H19 closely associated with progressive gastric cancer, and it could be a potential non-invasive 
diagnostic gastric cancer biomarker for management. Better  performance could be achieved 
lncRNA Functions Detection in cancer References
UCA1 1. Promotes the 
tumorigenesis, enhances 
cell proliferation, migration
PaCa, endometrial cancer, 
colorectal cancer, RCC, 
NSCLC, prostate cancer
[118, 191–194]
2. Contributes to the 
progression and prognosis
OSCC, ESCC [195, 196]
3. Promotes EMT BC [197]
4. Suppress metastasis Epithelial OC [198]
5. Modulates cell growth 
and apoptosis, and 
epigenetic regulation
BC [199, 200]
6. Enhances drug resistance BC, bladder cancer, GC, 
colorectal cancer, prostate 
cancer
[192, 201–205]
7. Promotes glutamine 
metabolism
Bladder cancer [206]
8. As diagnostic and 
prognostic markers
HCC, colon cancer (serum), 
early gastric cancer, lung 
cancer (plasma), bladder 
cancer (urine and blood),
[171, 207–217]
TUG1 1. Promotes cell 
proliferation, migration
Bladder cancer, BC, 
osteosarcoma, ESCC, HCC
[218–222]
2. Poor prognosis and 
promotes metastasis
Bladder cancer, GC, 
colorectal cancer, OC
[219, 223–226]
3. Associated with 
chemotherapy resistance 
and poor prognosis
ESCC [227]
4. Acts as a tumor 
suppressor in human 
glioma
Human glioma [228]
5. Affects apoptosis and 
insulin secretion
PaCa [124]
6. As biomarker for poor 
prognosis
Osteosarcoma (plasma), 
B-cell neoplasms (plasma)
[229, 230]
Table 1. Long non-coding RNAs (lncRNAs) as potential biomarkers for cancer.
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using both carcinoembryonic antigen (CEA) and H19 simultaneously [88]. Plasma H19 levels 
have been shown to be significantly decreased in postoperative breast cancer samples com-
pared to those in preoperative samples [89]. Urothelial cancer-associated 1 (UCA1), originally 
identified as a lncRNA in bladder cancer, has been proven to play a pivotal role in bladder 
cancer progression and embryonic development. Upregulation of the lncRNA UCA1 and the 
lncRNA WRAP53 has been observed in hepatocellular carcinoma (HCC), and CA1 might serve 
as a novel serum biomarker for HCC. Moreover, the expression levels of UCA1 and WRAP53 
in tissue have been shown to be strongly correlated with their levels in sera. Further, the com-
bination of UCA1 and WRAP53 with serum alpha fetoprotein could improve sensitivity to 
100% [90]. Further, meta-analysis also found that higher levels of UCA1 were correlated with 
shorter progression-free survival (PFS) and overall survival (OS) times in cancer [91], indicat-
ing that circulating lncRNAs, such as MALAT-1, PVT1, HOTAIR, H19, UCA1, and WRAP53, 
could serve as novel biomarkers for the early detection and the prediction of prognosis of 
cancer.
6. Exosomes and lncRNAs in the diagnosis and treatment of pancreatic 
cancer
Pancreatic cancer is one of the most lethal tumors, and its main tumor type is that of adeno-
carcinoma [92–94]. Pancreatic ductal adenocarcinoma (PDAC), the fourth leading cause of 
cancer-related deaths in both males and females in the USA, is usually asymptomatic [186], 
and PDAC is one of the most lethal malignant neoplasms worldwide [89, 95, 96]. Statistical 
analysis indicated that death rates rose from 2001 to 2010 [97]. In America, approximately 
53,000 people were diagnosed with pancreatic cancer in 2016, and pancreatic cancer was 
responsible for 41,750 deaths in the USA [98] in that same year. Additionally, the incidence of 
pancreatic cancer has shown an increasing trend year-by-year in China, and pancreatic cancer 
has become one of the top 10 causes of cancer-related deaths [99].
It is well known that pancreatic cancer has a poor prognosis because it is usually diagnosed 
after the cancer has already spread, leading to poor patient outcomes. Pancreatic ductal ade-
nocarcinoma patients have a 5-year survival rate of ~5% [100]. Survival can be improved 
if tumors are detected at an early stage, and the 5-year survival rate is 50% if tumors are 
<2 cm in size [101]. However, there have been no reliable biomarkers to accurately diag-
nose, image, or predict the tumor classification and biological behavior of pancreatic cancer 
until now. Thus, it is urgent to screen potential biomarkers and treatment-related biomark-
ers, such as exosome-derived proteins, DNA (exoDNA), miRNAs (exosomal miRNAs), and 
lncRNAs (exosomal lncRNAs), for the early detection of pancreatic cancer. Allenson found 
that KRAS mutations in the exoDNA of control, localized, locally advanced, and metastatic 
PDAC patients were 7.4, 66.7, 80, and 85%, respectively, which demonstrates that KRAS in 
exosomes could be applied to diagnose PDAC [102]. Takikawa also confirmed that pancreatic 
stellate cell (PSC)-derived exosomes stimulate the proliferation and migration of pancreatic 
cancer cells and upregulate the mRNA expression of the chemokine (C-X-C motif) ligands 1 
and 2 in pancreatic cancer cells [103]. Over the last few years, non-coding RNAs, especially 
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exosomal lncRNAs and exosomal miRNAs, have become a new diagnostic, prognostic, and 
predictive tool for pancreatic cancer. Exosomal miR-155, miR-196a, miR-17-5p, miR-10b, and 
miR-21 have good sensitivity and specificity in the serum of PaCa patients and can be useful 
serum biomarkers for pancreatic cancer [104, 105]. Not only can single exosomes be a diagno-
sis biomarker, but combined exosomal miRNAs, such as miR-1246, miR-4644, miR-3976, and 
miR-4306, can also increase sensitivity and specificity for the diagnosis of pancreatic cancer.
Specifically, exosomal lncRNAs have been identified as potential biomarkers of various can-
cers in recent years, including gastric cancer, breast cancer, and lung cancer. However, few 
studies have explored the potential use of exosomal lncRNAs in pancreatic cancer detection 
and prognosis. MALAT-1, HOTTIP, PVT1, and HOTAIR, which are secreted from PDAC cells 
to bodily fluids, such as blood, pancreatic juice, cystic fluid, and urine, are some of most widely 
studied lncRNAs in pancreatic cancer (Figure 1). As a potential oncogenic lncRNA, MALAT-1 
involves in proliferation, migration, and invasion and promotes the undifferentiated phe-
notype of pancreatic tumor cells [106]. MALAT-1 can also promote the tumorigenicity of 
pancreatic cancer cells, increase the proportion of pancreatic cancer stem cells, maintain a self-
renewing capacity, and decrease chemosensitivity to anticancer drugs. Moreover, MALAT-1 
has potential effects on the stem cell-like phenotypes of pancreatic cancer cells, which suggests 
that MALAT-1 has a novel role in tumor stemness [107]. The lncRNA HOTTIP enhances pan-
creatic cancer cell proliferation, survival, and migration and has been implicated in pancreatic 
cancer diagnosis and prognosis [108]. The overexpression of HOTAIR has been described as a 
poor prognostic factor in PDAC and can also be a novel non-invasive salivary biomarker for 
the early diagnosis of PaCa with PVT1 expression [109]. Increased expression of the lncRNA 
PVT1 is associated with poor prognosis in pancreatic cancer patients [110]. PVT1 expression is 
Figure 1. Exosomal lncRNAs secreted from PDAC cells as potential biomarkers of pancreatic cancer.
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significantly increased in PDAC and is correlated with tumor progression. Moreover, patients 
with high PVT1 expression levels have been shown to have shorter overall survival times com-
pared to those with low PVT1 expression levels, which implies that PVT1 could be a potential 
molecular biomarker for predicting the prognosis of patients with PDAC [110]. H19 has been 
shown to be overexpressed in PDAC tissues and to be correlated with the histological grade of 
PDAC. Knockdown of H19 can suppress cell viability, proliferation, and tumor growth, while 
H19 overexpression can enhance cell viability, proliferation, and tumor growth [111]. UCA1 
expression has been shown to be significantly upregulated in PaCa tumor tissues and to be 
significantly correlated with malignant potential factors, such as tumor size, depth of invasion, 
CA19-9 levels, and tumor stage. Highly expressed UCA1 has been shown to be an indepen-
dent prognostic biomarker of PaCa, leading to an obviously shorter 5-year overall survival 
(OS). Downregulation of UCA1 could effectively inhibit cell proliferative activities, which 
implies that UCA1 could be a potential prognostic biomarker and therapy target of PaCa [112].
In addition, high expression levels of the lncRNA HOXA13 have been shown to be correlated 
with lymph node metastasis, poor histological differentiation, and decreased overall survival 
in PDAC patients. The knockdown of HOXA13 resulted in proliferation arrest and impaired 
cell invasion in pancreatic cancer [113]. Using microarray analysis, HOTTIP was confirmed 
to be one of the most significantly upregulated lncRNAs in PDAC [113]. HOTTIP has been 
shown to be overexpressed in pancreatic cancer, and knockdown of HOTTIP in pancreatic can-
cer cells decreased proliferation, induced apoptosis, and decreased migration [108]. Using an 
Arraystar Human lncRNA Microarray, HOTTIP-005, XLOC_006390, and RP11-567G11.1 were 
found to be the most increased lncRNAs in PaCa. Elevated HOTTIP-005 and RP11-567G11.1 
expression could serve as poor prognostic markers for patients with PaCa. Plasma HDRF and 
RDRF (HOTTIP-005- and RP11-567G11.1-derived RNA fragments in plasma/serum) have also 
shown to be significantly increased in patients with PaCa, which demonstrates that HDRF 
and RDRF levels could be promising indicators for distinguishing patients with PC [114]. As 
an oncogenic lncRNA, uc.345 has been shown to promote tumor progression and to serve as 
a poor predictor for OS in pancreatic cancer patients. uc.345 was found to be upregulated in 
tumor tissues, and higher uc.345 expression levels have been associated with cancer invasion 
and metastasis, which could be an independent risk factor for the OS of pancreatic cancer 
patients [115]. The lncRNA IRAIN plays an important role in many malignancies, and upreg-
ulation of IRAIN has been shown to be significantly correlated with tumor size, the TNM 
classification of malignant tumors (TNM) stage, and lymph node metastasis in PaCa patients. 
The knockdown of IRAIN significantly induced cell apoptosis and inhibited cell proliferation 
in PaCa cells [116]. The lncRNA TUG1 has been shown to be highly expressed in pancreatic 
tissue compared with its expression in other organ tissues, and downregulation of TUG1 has 
been shown to affect apoptosis and insulin secretion in pancreatic β cells [117]. CCDC26 might 
be identified as a novel oncogene in PaCa by regulating proliferating cell nuclear antigen 
(PCNA) and Bcl2 expression. CCDC26 is significantly upregulated in PaCa, and it is corre-
lated with tumor size, tumor number, and reduced OS [118]. Univariate and multivariate 
analysis showed that CCDC26 expression can be an independent prognostic factor of OS in 
patients with PaCa; therefore, CCDC2 could serve as a novel biomarker and therapeutic target 
of PC for cancer in the future [118]. LINC-ROR has been shown to be upregulated in PaCa 
tissues, and overexpression of LINC-ROR promoted cell proliferation, migration, invasion, 
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and metastasis both in vitro and in mouse models. LINC-ROR acts as an important regula-
tor of ZEB1 and might represent a novel therapeutic target [119]. The lncRNA LINC-PINT 
(p53-induced transcript) could also regulate tumor cell viability and proliferation. However, 
the expression levels of LINC-PINT have been shown to be lower in plasma and tumor tissue 
samples in PaCa patients. LINC-PINT has been shown to be more sensitive than CA19-9 in 
detecting PaCa, which suggests that LINC-PINT could be used for distinguishing the cause 
of malignant obstructive jaundice [120]. The lncRNA HMlincRNA717 has also been shown 
to be downregulated in pancreatic cancer and associated with overall survival, suggesting 
that HMlincRNA717 could be a potential prognostic biomarker for pancreatic cancer progres-
sion [121]. As a potential tumor suppressor, the long intergenic non-coding RNA (lincRNA) 
LINC00673 has been associated with pancreatic cancer risk. A G>A mutation at rs11655237 
of LINC00673 created a target site for miR-1231 binding, which diminished the effect of 
LINC00673 in an allele-specific manner and conferred susceptibility to PaCa [122].
All the abovementioned exosomal lncRNAs could serve as diagnostic and prognostic factors to 
complement clinical and pathological parameters in predicting the outcome of patients with pan-
creatic cancer. Although there are an increasing number of clinical assays for studying exosomes, 
determining clinical applications for lncRNAs and exosomes is a long ways off. No matter how 
exosomes have become the most effective cancer vaccines, future research to investigate exo-
somal lncRNAs as biomarkers for the early detection of pancreatic cancer and to assess the valid-
ity and quality of the exosomes as effective vaccines for pancreatic cancer will be valuable. To 
achieve this long-term goal, further understanding of exosome biology, especially of the molecu-
lar mechanisms of tumor- and immune cell-derived exosomes as cancer vaccines, is required.
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